Kenneth Widder - Evoke Pharma Director
| EVOK Stock | USD 0.48 0.07 12.73% |
Director
Kenneth J. Widder, M.D. is member of our board of directors since June 2007. Dr. Widder has 32 years of experience working with biomedical companies. Dr. Widder was a General Partner with Latterell Venture Partners since 2007 and serves on the boards of Quidel Corporationrationration, Naurex Inc., Vision of Children, and the San Diego Museum of Art. Dr. Widder has founded seven companies and was Chairman and Chief Executive Officer of five of these companies. His last company, Sytera Inc., merged with Sirion Therapeutics, an ophthalmology specialty pharmaceutical company. Prior to Sytera, Dr. Widder cofounded and was the initial Chief Executive Officer of NovaCardia, Inc., a company acquired by Merck Co., Inc. Prior to NovaCardia, Dr. Widder founded and was Chairman and Chief Executive Officer of Santarus, Inc., which was acquired by Salix Pharmaceuticals in 2013. Additionally, Dr. Widder was Chairman and Chief Executive Officer of Converge Medical, Inc., a medical device company developing a sutureless anastamosis system for vein grafts in coronary bypass surgery. Dr. Widder started his career as a founder, Chairman and Chief Executive Officer of Molecular Biosystems, where he was responsible for the development and approval of Albunex and Optison, the first two ultrasound contrast agents to be approved in the United States. Dr. Widder is an inventor on over 30 patents and patent applications and has authored or coauthored over 25 publications. Dr. Widder holds an M.D. from Northwestern University and trained in pathology at Duke University. Dr. Widders extensive knowledge of our business and history, experience as a board member of multiple publiclytraded and privatelyheld companies and expertise in developing and financing contributed to our board of directors conclusion that he should serve as a director of our company. since 2007.
| Age | 65 |
| Tenure | 17 years |
| Address | 420 Stevens Avenue, Solana Beach, CA, United States, 92075 |
| Phone | 858 345 1494 |
| Web | https://evokepharma.com |
Evoke Pharma Management Efficiency
The company has return on total asset (ROA) of (0.4909) % which means that it has lost $0.4909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.3544) %, meaning that it created substantial loss on money invested by shareholders. Evoke Pharma's management efficiency ratios could be used to measure how well Evoke Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 3.17 this year, although the value of Return On Tangible Assets will most likely fall to (1.16). At this time, Evoke Pharma's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to about 101.4 K this year, although the value of Total Current Liabilities will most likely fall to about 2.3 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Alfred Sandrock | Neurocrine Biosciences | 60 | |
| Edward Owens | Ironwood Pharmaceuticals | 71 | |
| Stephen Sherwin | Neurocrine Biosciences | 69 | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
| Catherine Moukheibir | Ironwood Pharmaceuticals | 58 | |
| David Anstice | Alkermes Plc | 69 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Natale Ricciardi | Dynavax Technologies | 69 | |
| Julie McHugh | Ironwood Pharmaceuticals | 60 | |
| James Bristol | Deciphera Pharmaceuticals LLC | 71 | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| Marsha Fanucci | Ironwood Pharmaceuticals | 64 | |
| Edward Benz | Deciphera Pharmaceuticals LLC | 71 | |
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| Douglas Williams | Ironwood Pharmaceuticals | 59 | |
| Patricia Allen | Deciphera Pharmaceuticals LLC | 56 | |
| George Morrow | Neurocrine Biosciences | 66 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Liam Ratcliffe | Deciphera Pharmaceuticals LLC | 53 | |
| Marla Kessler | Ironwood Pharmaceuticals | 48 | |
| Peggy Phillips | Dynavax Technologies | 64 | |
Management Performance
| Return On Equity | -10.35 | ||||
| Return On Asset | -0.49 |
Evoke Pharma Leadership Team
Elected by the shareholders, the Evoke Pharma's board of directors comprises two types of representatives: Evoke Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evoke. The board's role is to monitor Evoke Pharma's management team and ensure that shareholders' interests are well served. Evoke Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evoke Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David RPh, CEO CoFounder | ||
| Ann Rhoads, Director | ||
| Marilyn Carlson, Chief Medical Officer | ||
| Matthew DOnofrio, Executive Vice President Chief Business Officer Treasurer, Secretary , | ||
| Kenneth Widder, Director | ||
| Ken Widder, Director | ||
| David Gonyer, CEO, Founder, Director | ||
| Matthew MBA, President CoFounder | ||
| Scott Glenn, Board Member | ||
| Cam Garner, Co-Founder, Chairperson and Chairman of Compensation Committee | ||
| DMD MD, Chief Officer | ||
| Christopher Quesenberry, Chief Gimoti | ||
| Todd Brady, Board Member |
Evoke Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evoke Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.35 | ||||
| Return On Asset | -0.49 | ||||
| Profit Margin | (1.50) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 4.25 M | ||||
| Shares Outstanding | 8.48 M | ||||
| Shares Owned By Insiders | 9.64 % | ||||
| Shares Owned By Institutions | 29.98 % | ||||
| Number Of Shares Shorted | 53.37 K | ||||
| Price To Earning | (3.21) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Evoke Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Evoke Pharma's short interest history, or implied volatility extrapolated from Evoke Pharma options trading.
Pair Trading with Evoke Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evoke Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evoke Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Evoke Stock
| 0.67 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.66 | ME | 23Andme Holding | PairCorr |
Moving against Evoke Stock
| 0.75 | DSGN | Design Therapeutics Downward Rally | PairCorr |
| 0.69 | YS | YS Biopharma Report 22nd of April 2024 | PairCorr |
| 0.63 | DOMH | Dominari Holdings | PairCorr |
| 0.61 | VCEL | Vericel Corp Ord Downward Rally | PairCorr |
| 0.56 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
The ability to find closely correlated positions to Evoke Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evoke Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evoke Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evoke Pharma to buy it.
The correlation of Evoke Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evoke Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evoke Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evoke Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Evoke Stock analysis
When running Evoke Pharma's price analysis, check to measure Evoke Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evoke Pharma is operating at the current time. Most of Evoke Pharma's value examination focuses on studying past and present price action to predict the probability of Evoke Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evoke Pharma's price. Additionally, you may evaluate how the addition of Evoke Pharma to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Evoke Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 1.55 | Quarterly Revenue Growth 1.105 | Return On Assets (0.49) | Return On Equity (10.35) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.